Nuvation Bio rises as brain cancer drug data spur expansion of studies

Nuvation Bio

20/07/2026 14:51

** Shares of cancer treatment firm Nuvation Bio NUVB.N rise 5.3% to $6.11 
** Co says its experimental brain cancer drug, safusidenib, showed a 52% confirmed response rate in patients with IDH1-mutant glioma, a common type of brain tumor caused by a gene mutation
** Says nearly 80% of patients were alive without their disease worsening three years after starting treatment in a Japanese mid-stage study
** Co will start a late-stage study outside the U.S. in about 140 newly diagnosed patients who have not received chemotherapy or radiation
** Says safusidenib's safety profile remained manageable
** Including session's move, stock down ~32% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))